The cell cycle molecules behind neurodegeneration in Alzheimer's disease: Perspectives for drug development(615 views) Copani A, Guccione S, Giurato L, Caraci F, Calafiore M, Sortino MA
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2008; 15(24): 2420-2432.
Keywords: β-Amyloid, Alzheimer, S Disease, Apoptosis, Cell Cycle, Cyclin-Dependent Kinases, Dna Polymerase-β, Dna Replication, Neuroprotection, Amyloid Beta Protein, Cyclin Dependent Kinase 1, Cyclin Dependent Kinase Inhibitor, Dna Directed Dna Polymerase Beta, Flavopiridol, Mimosine, Olomoucine, Protein P53, Roscovitine, Zalcitabine, Neuroprotective Agent, Alzheimer Disease, Binding Site, Cell Cycle Arrest, Cell Cycle G1 Phase, Cell Cycle Progression, Cell Cycle S Phase, Cell Proliferation, Clinical Trial, Creatinine Blood Level, Diarrhea, Dna Repair, Dna Synthesis, Drug Efficacy, Drug Eruption, Drug Potency, Drug Selectivity, Drug Structure, Drug Targeting, Gene Activation, Gene Mutation, Gene Targeting, Human, Nausea, Nerve Degeneration, Neurofibrillary Tangle, Nonhuman, Pathogenesis, Review, Side Effect, Vomiting, Animal, Biological Model, Drug Effect, Drug Screening, Metabolism, Pathology, Drug Evaluation, Preclinical, Neurological,
Affiliations: *** IBB - CNR ***
Department of Pharmaceutical Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy
I.B.B., CNR-Catania, Catania, Italy
Department of Experimental and Clinical Pharmacology, University of Catania, Viale A. Doria 6, 95125 Catania, Italy
Department of Human Physiology and Pharmacology, University of Rome La Sapienza, Italy
I.N.M. Neuromed, Pozzilli, Italy
I. B. B., CNR-Catania, Catania, Italy
I. N. M. Neuromed, Pozzilli, Italy
References: Not available.
The cell cycle molecules behind neurodegeneration in Alzheimer's disease: Perspectives for drug development
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(451 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote